Clinical, radiological, and biomarker outcomes following a switch from MabThera® to the rituximab biosimilar Rixathon® in multiple sclerosis. // Multiple Sclerosis and Related Disorders. – URL: https://www.sciencedirect.com/science/article/pii/S2211034826010898?dgcid=rss_sd_all
Clinical, radiological, and biomarker outcomes following a switch from MabThera® to the rituximab biosimilar Rixathon® in multiple sclerosis. Multiple Sclerosis and Related Disorders. https://www.sciencedirect.com/science/article/pii/S2211034826010898?dgcid=rss_sd_all
“Clinical, radiological, and biomarker outcomes following a switch from MabThera® to the rituximab biosimilar Rixathon® in multiple sclerosis.” Multiple Sclerosis and Related Disorders.
@article{article9024,
title = {Clinical, radiological, and biomarker outcomes following a switch from MabThera® to the rituximab biosimilar Rixathon® in multiple sclerosis},
journal = {Multiple Sclerosis and Related Disorders},
url = {https://www.sciencedirect.com/science/article/pii/S2211034826010898?dgcid=rss_sd_all}
}